4 research outputs found
Convergent validity of the PsAQoL.
<p>PsAQoL, psoriatic arthritis quality of life; HAQ, health assessment questionnaire; Skin-17, Skindex-17.</p>*<p>P<0.01.</p
Scores on the PsAQoL, HAQ and Skindex-17 at first and second assessment.
<p>PsAQoL, psoriatic arthritis quality of life; HAQ, health assessment questionnaire; Skin-17, Skindex-17; N, number of patients.</p
Characteristics of the psoriatic arthritis (PsA) study population.
<p>Data obtained from self-reports.</p>A<p> = responders 1<sup>st</sup> series of questionnaires;</p>B<p> = 1<sup>st</sup> series PsAQoL complete; used for internal con- sistency assessment;</p>C<p> = 1<sup>st</sup> and 2<sup>nd</sup> series PsAQoL complete; used for calculating test-retest reliability;</p>D<p> = 1<sup>st</sup> series PsAQoL, HAQ and Skindex complete; used for convergent validity analyses.</p><p>PsA, psoriatic arthritis; n, number; y, years; SD, standard deviation; DMARD, disease-modifying antirheumatic drugs; anti-TNFα, anti-tumor necrosis factor α; NSAID, non-steroidal anti- inflammatory drug; PsAQoL, psoriatic arthrtitis quality of life; HAQ, health assessement questionnaire.</p
Bland-Altman plot PsAQoL.
<p>Difference between the 1<sup>st</sup> and 2<sup>nd</sup> PsAQoL plotted against the mean of both assessments. PsAQoL, Psoriatic Arthritis Quality of Life; LOA, limits of agreement; CI, confidence interval.</p